Xintela signs Letter of Intent with CO.DON
Xintela AB (publ) announces today that the company has signed a Letter of Intent with the leading European cell therapy company CO.DON. The parties intend to co-develop a stem cell product for the treatment of osteoarthritis, based on Xintela’s stem cell technology. CO.DON will pay an exclusivity fee for a 6- month period, during which […]
Xintela receives MUMS-status for the treatment of osteoarthritis in horses
Lund, Sweden, 28th of June 2018 – Xintela announces today that the company has received MUMS-status (Minor Use Minor Species) in Europe for the treatment of degenerative joint disease, including osteoarthritis, in horses. MUMS-status is the veterinary equivalent of Orphan Drug in human medicine. The MUMS classification gives a significant reduction of documentation requirements prior […]
Xintela’s GMP facility is completed and being prepared for production and clinical trials
Xintela AB (publ) today announced that the GMP facility is completed and that the company has moved to offices and laboratories in direct conjunction with the GMP facility. It will now be equipped with instruments and prepared for inspection and approval by the Medical Products Agency for manufacturing licenses for clinical studies. The facility is […]
Xintela develops unique methods in stem cell therapy for the brain and broadens patent portfolio
Lund, Sweden, 17th of April 2018 – Xintela AB (publ) has developed new methods for identifying and purifying neural stem cells from the brain. This opens up a completely new field within the company’s cell therapy business for the treatment of traumatic damage and diseases of the central nervous system (CNS). “We believe this has […]
Xintela prepares for oncology spinout
Xintela AB (publ) announces today that the company has decided to prepare for a possible spin-out of its oncology business into a separate company to be distributed to Xintelas existing shareholders through a stock dividend and listed on a suitable stock market during 2018. Since 2014, Xintela’s cancer project focusing on the aggressive brain tumor […]
Xintela licenses human antibody technology for cancer therapy
Xintela AB (publ) today announced the company has licensed antibody technology for the development of human antibodies in diagnostics and therapy. The antibodies, directed to Xintela’s markers integrin 101 och integrin 111, are already adapted for human use. This means that Xintela saves both time and money and that Xintela’s cancer products can be tested […]
Xintela to collaborate with Japanese CellSeed Inc.
Xintela AB (publ) announces today that the company has signed a collaboration agreement with the leading Japanese cell therapy company, CellSeed, for its development of a cell therapy product for the treatment of cartilage damage in the knee joint. “It is very exciting that we have established a collaboration in Japan which, due to a […]
Xintela raises 17 million SEK in debt and equity
Xintela AB (publ) announces a directed share issue of approximately 10 million SEK and borrowing of 7 million SEK to strengthen its working capital for investment in Xintela’s development programs. The Board of Xintela, under the authorization adopted at the AGM on 18 May 2017, today decided to issue a total of 3,205,129 new shares, […]
Keld Søndergaard leaves Xintela’s Board of Directors
Xintela AB (publ) announces that Keld Søndergaard has resigned from the company’s Board of Directors, citing personal reasons. Xintela’s larger shareholders, acting as an informal nomination committee, will consider potential replacement candidates to propose to the next Annual General Meeting. Keld Søndergaard was elected as a new member of the Board at the Annual General […]
Xintela building own GMP-facility for stem cell production
Xintela AB (publ) announces the company has decided to bring forward the construction of its own facility for production of equine and human stem cell-based ATMPs (Advanced Therapy Medicinal Products) at Medicon Village, Lund. Initially, stem cells will be produced for clinical studies in horses. After careful evaluation of available options, Xintela has decided to […]
